NCT04609943View on ClinicalTrials.gov

Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS)

PHASE1TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 24, 2020

Primary Completion Date

August 17, 2023

Study Completion Date

September 14, 2023

Conditions
Acute Respiratory Distress Syndrome
Interventions
DRUG

BAY1211163

Participants will receive one of the drug doses of BAY1211163 solution three times per day (TID) by inhalation for seven days.

Trial Locations (4)

10117

Charité - Universitätsmedizin Berlin, Berlin

35392

Universitätsklinikum Giessen und Marburg, Giessen

51109

Klinikum der Stadt Köln gGmbH - Krankenhaus Merheim, Cologne

North Rhine-Westphalia

"Sana-Klinikum Remscheid, Kardio, Angio, Pneumo u. Intensivmed"

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT04609943 - Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) | Biotech Hunter | Biotech Hunter